Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma
Objective To determine whether a fraction of patients with primary CNS lymphoma (PCNSL) had been cured by systemic and intraventricular methotrexate- and cytarabine-based chemotherapy (Bonn protocol) after a very long-term follow-up of nearly 20 years. - Methods Sixty-five patients (median age 62 ye...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
September 28, 2020
|
| In: |
Neurology
Year: 2020, Volume: 95, Issue: 23, Pages: e3138-e3144 |
| ISSN: | 1526-632X |
| DOI: | 10.1212/WNL.0000000000010949 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1212/WNL.0000000000010949 Verlag, lizenzpflichtig, Volltext: https://n.neurology.org/content/95/23/e3138 
|
| Author Notes: | Sabine Seidel, MD, Hendrik Pels, MD, Sabine Schlömer, PhD, Annika Kowoll, MD, Klaus Fliessbach, MD, PhD, Andreas Engert, MD, Marlies Vogt-Schaden, MD, Gerlinde Egerer, MD, Heinz Reichmann, MD, PhD, Gabriele Schackert, MD, Frank Kroschinsky, MD, Martina Deckert, MD, Ulrich Herrlinger, MD, Thomas Klockgether, MD, PhD, Rolf Fimmers, PhD, Udo Bode, MD, Ingo G.H. Schmidt-Wolf, MD, and Uwe Schlegel, MD |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 175042696X | ||
| 003 | DE-627 | ||
| 005 | 20230427140038.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210304s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1212/WNL.0000000000010949 |2 doi | |
| 035 | |a (DE-627)175042696X | ||
| 035 | |a (DE-599)KXP175042696X | ||
| 035 | |a (OCoLC)1341397158 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Seidel, Sabine |d 1984- |e VerfasserIn |0 (DE-588)1178747980 |0 (DE-627)1049622987 |0 (DE-576)511294220 |4 aut | |
| 245 | 1 | 0 | |a Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma |c Sabine Seidel, MD, Hendrik Pels, MD, Sabine Schlömer, PhD, Annika Kowoll, MD, Klaus Fliessbach, MD, PhD, Andreas Engert, MD, Marlies Vogt-Schaden, MD, Gerlinde Egerer, MD, Heinz Reichmann, MD, PhD, Gabriele Schackert, MD, Frank Kroschinsky, MD, Martina Deckert, MD, Ulrich Herrlinger, MD, Thomas Klockgether, MD, PhD, Rolf Fimmers, PhD, Udo Bode, MD, Ingo G.H. Schmidt-Wolf, MD, and Uwe Schlegel, MD |
| 264 | 1 | |c September 28, 2020 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 04.03.2021 | ||
| 520 | |a Objective To determine whether a fraction of patients with primary CNS lymphoma (PCNSL) had been cured by systemic and intraventricular methotrexate- and cytarabine-based chemotherapy (Bonn protocol) after a very long-term follow-up of nearly 20 years. - Methods Sixty-five patients (median age 62 years, range 27-75; median Karnofsky performance score 70, range 20-90) had been treated with systemic and intraventricular polychemotherapy without whole brain radiotherapy from September 1995 until December 2001. All patients still alive in 2019 were contacted and interviewed on their current life situation. - Results Median follow-up for surviving patients was 19.6 years (17.5-23.3 years). Out of 65 patients, 11 (17%) were still alive. Six of those never experienced any relapse. For the whole study population, median overall survival (OS) was 4.4 years (95% confidence interval [CI] 2.9-5.9); for patients ≤60 years, 11.0 years (95% CI 4.8-17.0). The 10-year OS rate for the entire cohort was 29% and the estimated 20-year OS rate was 19%. Four late relapses were observed after 9.8, 10.3, 13.3, and 21.0 years. - Conclusion At a median follow-up of 19.6 years, 17% of patients were alive and free of tumor; however, even after response for decades, an inherent risk of relapse, either systemic or cerebral, characterizes the biology of PCNSL. - Classification of evidence This work provides Class III evidence that PCNSL treatment with methotrexate-based polychemotherapy including intraventricular therapy is associated with long-term disease control in some patients. | ||
| 700 | 1 | |a Pels, Hendrik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schlömer, Sabine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kowoll, Annika |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fliessbach, Klaus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Engert, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vogt-Schaden, Maria-Elisabeth |e VerfasserIn |0 (DE-588)1124112871 |0 (DE-627)877846464 |0 (DE-576)17151663X |4 aut | |
| 700 | 1 | |a Egerer, Gerlinde |e VerfasserIn |0 (DE-588)105502168X |0 (DE-627)792516745 |0 (DE-576)167430882 |4 aut | |
| 700 | 1 | |a Reichmann, Heinz |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schackert, Gabriele |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kroschinsky, Frank |e VerfasserIn |4 aut | |
| 700 | 1 | |a Deckert, Martina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Herrlinger, Ulrich |e VerfasserIn |4 aut | |
| 700 | 1 | |a Klockgether, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fimmers, Rolf |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bode, Udo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmidt-Wolf, Ingo G. H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schlegel, Uwe |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurology |d Philadelphia, Pa. : Wolters Kluwer, 1951 |g 95(2020), 23, Seite e3138-e3144 |h Online-Ressource |w (DE-627)302718524 |w (DE-600)1491874-2 |w (DE-576)079876609 |x 1526-632X |7 nnas |a Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma |
| 773 | 1 | 8 | |g volume:95 |g year:2020 |g number:23 |g pages:e3138-e3144 |g extent:7 |a Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma |
| 856 | 4 | 0 | |u https://doi.org/10.1212/WNL.0000000000010949 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://n.neurology.org/content/95/23/e3138 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210304 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 105502168X |a Egerer, Gerlinde |m 105502168X:Egerer, Gerlinde |d 910000 |d 910100 |d 50000 |e 910000PE105502168X |e 910100PE105502168X |e 50000PE105502168X |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 8 | ||
| 998 | |g 1124112871 |a Vogt-Schaden, Maria-Elisabeth |m 1124112871:Vogt-Schaden, Maria-Elisabeth |d 910000 |d 911100 |e 910000PV1124112871 |e 911100PV1124112871 |k 0/910000/ |k 1/910000/911100/ |p 7 | ||
| 999 | |a KXP-PPN175042696X |e 388176819X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"September 28, 2020"}],"recId":"175042696X","relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["302718524"],"issn":["1526-632X"],"zdb":["1491874-2"]},"disp":"Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphomaNeurology","note":["Gesehen am 12.12.23"],"origin":[{"dateIssuedDisp":"1951-","publisher":"Wolters Kluwer ; Ovid ; Lippincott Williams & Wilkins","dateIssuedKey":"1951","publisherPlace":"Philadelphia, Pa. ; [Erscheinungsort nicht ermittelbar] ; Hagerstown, Md."}],"recId":"302718524","type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.1951 -"],"title":[{"title":"Neurology","subtitle":"official journal of the American Academy of Neurology","title_sort":"Neurology"}],"part":{"pages":"e3138-e3144","extent":"7","issue":"23","volume":"95","text":"95(2020), 23, Seite e3138-e3144","year":"2020"},"language":["eng"]}],"note":["Gesehen am 04.03.2021"],"physDesc":[{"extent":"7 S."}],"id":{"doi":["10.1212/WNL.0000000000010949"],"eki":["175042696X"]},"name":{"displayForm":["Sabine Seidel, MD, Hendrik Pels, MD, Sabine Schlömer, PhD, Annika Kowoll, MD, Klaus Fliessbach, MD, PhD, Andreas Engert, MD, Marlies Vogt-Schaden, MD, Gerlinde Egerer, MD, Heinz Reichmann, MD, PhD, Gabriele Schackert, MD, Frank Kroschinsky, MD, Martina Deckert, MD, Ulrich Herrlinger, MD, Thomas Klockgether, MD, PhD, Rolf Fimmers, PhD, Udo Bode, MD, Ingo G.H. Schmidt-Wolf, MD, and Uwe Schlegel, MD"]},"person":[{"role":"aut","given":"Sabine","display":"Seidel, Sabine","family":"Seidel"},{"display":"Pels, Hendrik","given":"Hendrik","role":"aut","family":"Pels"},{"given":"Sabine","role":"aut","display":"Schlömer, Sabine","family":"Schlömer"},{"display":"Kowoll, Annika","role":"aut","given":"Annika","family":"Kowoll"},{"family":"Fliessbach","role":"aut","given":"Klaus","display":"Fliessbach, Klaus"},{"family":"Engert","given":"Andreas","role":"aut","display":"Engert, Andreas"},{"display":"Vogt-Schaden, Maria-Elisabeth","role":"aut","given":"Maria-Elisabeth","family":"Vogt-Schaden"},{"display":"Egerer, Gerlinde","role":"aut","given":"Gerlinde","family":"Egerer"},{"role":"aut","given":"Heinz","display":"Reichmann, Heinz","family":"Reichmann"},{"display":"Schackert, Gabriele","role":"aut","given":"Gabriele","family":"Schackert"},{"display":"Kroschinsky, Frank","given":"Frank","role":"aut","family":"Kroschinsky"},{"display":"Deckert, Martina","given":"Martina","role":"aut","family":"Deckert"},{"display":"Herrlinger, Ulrich","role":"aut","given":"Ulrich","family":"Herrlinger"},{"display":"Klockgether, Thomas","given":"Thomas","role":"aut","family":"Klockgether"},{"role":"aut","given":"Rolf","display":"Fimmers, Rolf","family":"Fimmers"},{"family":"Bode","display":"Bode, Udo","given":"Udo","role":"aut"},{"family":"Schmidt-Wolf","given":"Ingo G. H.","role":"aut","display":"Schmidt-Wolf, Ingo G. H."},{"display":"Schlegel, Uwe","role":"aut","given":"Uwe","family":"Schlegel"}],"language":["eng"],"title":[{"title":"Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma","title_sort":"Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma"}]} | ||
| SRT | |a SEIDELSABITWENTYYEAR2820 | ||